about
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheuma...
Read More
104.17
0.02
(0.02%)
1.4M
XNAS Volume
XNAS 17 Nov, 2025 4:30 PM (EST)
Board Meeting
The board meeting for Incyte Corp. is scheduled for today, for the purpose of Jefferies Global Healthcare Conference
See details
High Financial Strength
Affordable Valuation
Technically Bullish
Strong Performer
These stock companies have strong financials and are affordably priced. They also score high in quality and technical aspects which makes them a favourite amongst investors.
View Similar
Embed DVM
Incyte Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..